Received Apr 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
Menveo - vaccine reconstituted with sterile diluent instead of Men CWY component; Menveo - vaccine reconstituted with sterile diluent instead of Men CWY component; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On an unknown date, the patient received Menveo. On an unknown date, an unknown time after receiving Menveo, the patient experienced inappropriate preparation of medication (Verbatim: Menveo - vaccine reconstituted with sterile diluent instead of Men CWY component) and inappropriate dose of vaccine administered (Verbatim: Menveo - vaccine reconstituted with sterile diluent instead of Men CWY component). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK receipt date: 10-APR-2026 The Menveo vaccine that was mixed with a sterile diluent and not the MenCYW-135 Liquid Conjugate Component. It was administered to the patient. No further details provided. The batch number was not provided upon follow- up with the reporter.; Sender's Comments: US-GSK-US2026050366:Same reporter